These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35812443)

  • 1. Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer.
    Ju M; Fan J; Zou Y; Yu M; Jiang L; Wei Q; Bi J; Hu B; Guan Q; Song X; Dong M; Wang L; Yu L; Wang Y; Kang H; Xin W; Zhao L
    Front Immunol; 2022; 13():807840. PubMed ID: 35812443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer.
    Maeda S; Motegi T; Iio A; Kaji K; Goto-Koshino Y; Eto S; Ikeda N; Nakagawa T; Nishimura R; Yonezawa T; Momoi Y
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
    Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
    J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
    Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
    Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FoxP3
    Saleh R; Elkord E
    Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation on the regulatory T cells signature and relevant Foxp3/STAT3 axis in esophageal cancer.
    Yang L; Zhao Q; Wang X; Pilapong C; Li Y; Zou J; Jin J; Rong J
    Cancer Med; 2023 Feb; 12(4):4993-5008. PubMed ID: 36226375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.
    Karpisheh V; Mousavi SM; Naghavi Sheykholeslami P; Fathi M; Mohammadpour Saray M; Aghebati-Maleki L; Jafari R; Majidi Zolbanin N; Jadidi-Niaragh F
    Life Sci; 2021 Nov; 284():119132. PubMed ID: 33513396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
    Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
    Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
    Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
    Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment.
    Zhang G
    Front Immunol; 2022; 13():975762. PubMed ID: 36189226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revealing the role of regulatory T cells in the tumor microenvironment of lung adenocarcinoma: a novel prognostic and immunotherapeutic signature.
    Zhang P; Zhang X; Cui Y; Gong Z; Wang W; Lin S
    Front Immunol; 2023; 14():1244144. PubMed ID: 37671160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer.
    Zhang T; Li J; Dai J; Yuan F; Yuan G; Chen H; Zhu D; Mao X; Qin L; Liu N; Yang M
    Cancer Genet; 2023 Aug; 276-277():48-59. PubMed ID: 37487324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies.
    Nishikawa H; Koyama S
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
    Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
    Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of costimulatory and inhibitory receptors in FoxP3
    Toker A; Ohashi PS
    Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
    Stultz J; Fong L
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of a tumor-infiltrating Treg transcriptional signature conserved across species and tumor types.
    Magnuson AM; Kiner E; Ergun A; Park JS; Asinovski N; Ortiz-Lopez A; Kilcoyne A; Paoluzzi-Tomada E; Weissleder R; Mathis D; Benoist C
    Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10672-E10681. PubMed ID: 30348759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
    Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
    Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of regulatory T cells in cancer immunity.
    Takeuchi Y; Nishikawa H
    Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.